Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Pharma & Biotech
Pharma & Biotech
Could Novartis change the ITP playbook with just four doses of ianalumab?
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.
Medical Devices & Diagnostics
Can TrilliumBiO and Oncobit make MRD monitoring standard for uveal melanoma in the U.S.?
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.
Medical Devices & Diagnostics
Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.
Pharma & Biotech
MajesTEC-3 results put Johnson & Johnson’s bispecific combo at center of myeloma care debate
TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.
Pharma & Biotech
Is Eli Lilly’s Jaypirca now the most compelling single-agent therapy in untreated CLL?
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Pharma & Biotech
Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing
Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.
Medical Devices & Diagnostics
Can ProVee change how BPH is treated? FDA nod gives ProVerum its biggest win yet
ProVerum wins FDA approval for ProVee, a permanent urethral stent for BPH offering fast recovery and no catheter. See how it could disrupt the urology device market.
Pharma & Biotech
Eli Lilly targets first-line CLL with Jaypirca as BRUIN CLL-314 trends toward PFS benefit
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?
Medical Devices & Diagnostics
Johnson & Johnson targets earlier-line myeloma with CARVYKTI expansion
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?